Vestor Capital LLC Cuts Stake in Krystal Biotech, Inc. $KRYS

Vestor Capital LLC lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 93.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 200 shares of the company’s stock after selling 2,740 shares during the period. Vestor Capital LLC’s holdings in Krystal Biotech were worth $52,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Western Wealth Management LLC purchased a new position in Krystal Biotech during the first quarter worth about $34,000. Bank of America Corp DE boosted its holdings in Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock valued at $67,330,000 after purchasing an additional 69,840 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Krystal Biotech by 21.5% in the 1st quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock valued at $68,879,000 after purchasing an additional 47,219 shares in the last quarter. Cim LLC acquired a new position in Krystal Biotech during the 1st quarter worth approximately $3,872,000. Finally, Amundi raised its stake in shares of Krystal Biotech by 52.0% during the 1st quarter. Amundi now owns 5,706 shares of the company’s stock worth $1,474,000 after buying an additional 1,952 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on KRYS. Bank of America lifted their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, TD Cowen upped their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $360.67.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock worth $8,243,923 over the last quarter. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Down 7.0%

Shares of KRYS stock opened at $341.12 on Friday. The stock has a market cap of $10.06 billion, a P/E ratio of 45.60 and a beta of 0.50. Krystal Biotech, Inc. has a fifty-two week low of $130.50 and a fifty-two week high of $382.54. The business has a fifty day simple moving average of $339.70 and a 200-day simple moving average of $296.28.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.